European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Preparing for RSV Immunisation and Surveillance in Europe

Descrizione del progetto

DE EN ES FR IT PL

Sforzi integrati verso l’immunizzazione da VRS

Il virus respiratorio sinciziale (VRS) è altamente contagioso e colpisce i polmoni e le vie respiratorie. L’infezione da tale virus mostra uno schema stagionale e la sua manifestazione varia da sintomi tipici simil-influenzali alla malattia respiratoria grave in bambini piccoli e anziani. Per evitare le sue complicazioni potenzialmente letali, occorre introdurre al più presto un vaccino contro tale virus nei programmi nazionali di vaccinazione. Il progetto PROMISE, finanziato dall’UE, condurrà analisi epidemiologiche per raccogliere i dati da registri nazionali e da revisioni sistemiche, e convaliderà nuovi biomarcatori per l’infezione da tale virus. La creazione di un sistema a livello europeo per il monitoraggio del virus respiratorio sinciziale insieme al monitoraggio successivo all’immissione sul mercato e alla valutazione di vaccini contro tale virus in fase di sviluppo clinico avanzato fornirà ulteriori prove per la sicurezza e l’efficacia dell’immunizzazione da VRS.

Obiettivo

RSV causes severe disease in the very young and elderly and results in substantial healthcare costs. In the last 4 years, substantial progress has been made in development of products for active and passive immunization against RSV, with 19 products currently in clinical development. In 2017, we were funded by IMI to set up RESCEU project (Grant Agreement number 116019), which is the single largest consortium currently working on RSV and has addressed several of the key evidence gaps to inform the introduction of an RSV vaccine. However, new gaps in evidence have emerged and many key requirements for the introduction of a novel RSV vaccine into national immunisation programmes (not addressed within RESCEU) remain unmet. PROMISE’s vision is to seamlessly build on, exploit, and add value to the significant achievements of RESCEU to prepare for the imminent introduction of an RSV vaccine. Expanding the existing RESCEU network to include 5 new partners, PROMISE comprises of 5 distinct but inter-connected work packages (WPs). WP 1 will conduct epidemiological and cost-effectiveness analyses marshalling data from systematic reviews; national and regional disease registries; surveillance programmes and linked routine healthcare datasets. WP2 will foster a consensus and develop an operational plan for expanded coordinated RSV surveillance and reporting activities; post-licensure monitoring and evaluation of products for RSV immunization across Europe. WP3 will initiate new prospective studies to address key gaps in existing knowledge (RSV disease severity scores, asthma in school age children) and assemble biobanks for biomarker validation. WP4 will validate temporally and at mucosal level biomarkers that were identified in RESCEU adopting state of the art technologies. WPs 1-4 will develop high-quality, sustainable, robust data collection systems that link closely with public health/regulatory bodies/health care providers for informing policy and regulatory processes.

Campo scientifico

Parole chiave

Programma(i)

Argomento(i)

Invito a presentare proposte

H2020-JTI-IMI2-2020-22-single-stage

Vedi altri progetti per questo bando

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

THE UNIVERSITY OF EDINBURGH
Contribution nette de l'UE
€ 746 625,00
Indirizzo
OLD COLLEGE, SOUTH BRIDGE
EH8 9YL Edinburgh
Regno Unito

Mostra sulla mappa
Regione
Scotland Eastern Scotland Edinburgh
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 746 625,00

Partecipanti (22)

Condividi questa pagina

Scarica

Ultimo aggiornamento: 29 Aprile 2024

Il mio booklet

Permalink: https://cordis.europa.eu/project/id/101034339/it

European Union, 2024